Get started
Verve Therapeutics, Inc.Verve Therapeutics, Inc.Verve Therapeutics, Inc.

Verve Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

VERV chart


Full chart

VERV upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪365.84 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.35 USD
Net income (FY)
‪−198.71 M‬ USD
Revenue (FY)
‪32.33 M‬ USD
Shares float
‪66.12 M‬
Beta (1Y)
2.17

Employees


Employees (FY)
274
Change (1Y)
+19 +7.45%
Revenue / Employee (1Y)
‪118.00 K‬ USD
Net income / Employee (1Y)
‪−725.22 K‬ USD

About Verve Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Sekar Kathiresan
Website
vervetx.com
Headquarters
Boston
Founded
2018
FIGI
BBG00P33TCZ8
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VERV news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VERV.

Frequently Asked Questions


The current price of VERV is 4.97 USD — it has increased by 26.38% in the past 24 hours. Watch Verve Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Verve Therapeutics, Inc. stocks are traded under the ticker VERV.
VERV stock has risen by 20.47% compared to the previous week, the month change is a −34.08% fall, over the last year Verve Therapeutics, Inc. has showed a −35.71% decrease.
We've gathered analysts' opinions on Verve Therapeutics, Inc. future price: according to them, VERV price has a max estimate of 39.00 USD and a min estimate of 15.00 USD. Watch VERV chart and read a more detailed Verve Therapeutics, Inc. stock forecast: see what analysts think of Verve Therapeutics, Inc. and suggest that you do with its stocks.
VERV reached its all-time high on Sep 7, 2021 with the price of 78.00 USD, and its all-time low was 2.86 USD and was reached on Apr 9, 2025. View more price dynamics on VERV chart.
See other stocks reaching their highest and lowest prices.
VERV stock is 34.63% volatile and has beta coefficient of 2.17. Track Verve Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Verve Therapeutics, Inc. there?
Today Verve Therapeutics, Inc. has the market capitalization of ‪365.84 M‬, it has decreased by −19.23% over the last week.
Yes, you can track Verve Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Verve Therapeutics, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
VERV earnings for the last quarter are −0.58 USD per share, whereas the estimation was −0.68 USD resulting in a 14.13% surprise. The estimated earnings for the next quarter are −0.64 USD per share. See more details about Verve Therapeutics, Inc. earnings.
Verve Therapeutics, Inc. revenue for the last quarter amounts to ‪13.08 M‬ USD, despite the estimated figure of ‪3.93 M‬ USD. In the next quarter, revenue is expected to reach ‪9.01 M‬ USD.
VERV net income for the last quarter is ‪−50.03 M‬ USD, while the quarter before that showed ‪−50.13 M‬ USD of net income which accounts for 0.20% change. Track more Verve Therapeutics, Inc. financial stats to get the full picture.
No, VERV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 274 employees. See our rating of the largest employees — is Verve Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Verve Therapeutics, Inc. EBITDA is ‪−221.91 M‬ USD, and current EBITDA margin is −686.34%. See more stats in Verve Therapeutics, Inc. financial statements.
Like other stocks, VERV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Verve Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Verve Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Verve Therapeutics, Inc. stock shows the sell signal. See more of Verve Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.